RT Journal Article
SR Electronic
T1 Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy: Results of an Open Noncomparative Phase 2 Multicenter Italian Study (After-6 Protocol 2)
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 615-619
OP 615-619
DO 10.1111/IGC.0b013e3181a4476b
VO 19
IS 4
A1 Gadducci, Angiolo
A1 Katsaros, Dionyssios
A1 Zola, Paolo
A1 Scambia, Giovanni
A1 Ballardini, Michela
A1 Pasquini, Enzo
A1 Fertonani, Carlo
A1 Maggi, Lorenzo
A1 Pecorelli, Sergio
A1 Conte, Pier Franco
A1 other members of the After-6 Italian Cooperative Group
YR 2009
UL http://ijgc.bmj.com/content/19/4/615-619.abstract
AB The aim of this paper was to assess whether weekly intravenous 60-mg/m2 paclitaxel for 21 weeks is feasible and effective as maintenance treatment in 64 patients with advanced ovarian cancer who had microscopic residual disease after 6 cycles of paclitaxel/platinum-based chemotherapy. Forty-eight patients completed the planned cycles of weekly paclitaxel. The worst toxicities were grade 2 leukopenia in 22.4% of the patients, grade 2 neutropenia in 25.9%, grade 2 sensorial neurotoxicity in 20.7%, and grade 2 motor neurotoxicity in 6.9%. Seventeen patients underwent a third-look surgery that showed a pathological complete response in 6 (35.3%, 95% confidence interval [CI], 17.3%-59.0%) cases. The 3-year progression-free survival rate was 18% (95% CI, 9.6%-33.8%), and the 3-year overall survival rate was 64% (95% CI, 52.0%-78.0%). Weekly low-dose paclitaxel is a feasible and well-tolerated maintenance treatment.